ENZON's ONCASPAR APPROVED FEB. 1 FOR ACUTE LYMPHOBLASTIC LEUKEMIA
Executive Summary
ENZON's ONCASPAR APPROVED FEB. 1 FOR ACUTE LYMPHOBLASTIC LEUKEMIA in patients "who require L-asparaginase in their treatment regimen but have developed hypersensitivity to the native forms of L-asparaginase" (Merck's Elspar), labeling states. The approval of Enzon's second biological product follows a Dec. 3, 1993 "approvable" notification from FDA's Center for Biologics Evaluation & Research ("The Pink Sheet" Dec. 6, 1993, In Brief).